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Abstract
Background: The surgical technique used in liver transplantation has undergone constant evolution in an effort to
develop a safe, highly standardized procedure. Despite this, the initial step of recipient hepatectomy has not been
the focus of clinical research thus far. Due to advanced coagulopathy in liver transplant recipients, this part of the
operation still carries the risk of severe hemorrhage. This trial is designed to compare an electrothermal bipolar vessel
sealing device (LigaSure™) and an ultrasound dissector (HARMONIC ACE®+7) with standard surgical techniques during
the recipients’ hepatectomy in liver transplantation.
Methods/design: In a single-center, prospective, randomized, controlled, parallel, three-armed, confirmatory, open
trial, LigaSure™ and HARMONIC ACE®+7 will be compared with standard surgical techniques that use titanium clips
and conventional knot-tying ligations during recipient hepatectomy in liver transplantation. Intraoperative total blood
loss is the primary endpoint of the trial. Secondary endpoints include blood loss during hepatectomy, the duration of
both the hepatectomy and the entire surgical procedure, and blood transfusion requirements of the procedure. To
generate reliable data, intraoperative blood loss will be recorded with respect to all rinse fluids during surgery, ascites,
and by weighing used swabs. At 80% power and an alpha of 0.025 for both of the experimental groups, 23 subjects
will be analyzed per protocol in each study arm in order to detect clinically relevant reduction of intraoperative blood
loss. The intention-to-treat analysis will include 69 patients. The follow-up period for each patient will be 90 days for
safety reasons, whereas all clinical outcomes will be measured within the first 10 postoperative days.
Discussion: To our knowledge, this is the first prospective, randomized trial comparing two innovative technical
methods of vessel sealing and dissection with standard techniques for recipient hepatectomy. This will be done to
detect relevant reduction of intraoperative blood loss during liver transplant. The results of the trial are expected to
improve patient outcome and safety after liver transplant and to increase the general safety of this procedure.
Trial registration: ClinicalTrials.gov, NCT 03323242. Registered on October 26, 2017.
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Background
Liver transplant (LT) is a well-established procedure for the
treatment of end-stage liver disease. Many improvements
in the surgical technique have rendered this operation rela-
tively safe. Most important operative innovations after the
initial introduction of LT in the clinical routine undertaken
by Starzl include the use of venovenous bypass in LT [1, 2];
the piggyback technique with preservation of the recipients’
caval vein [3]; and its modification, which was introduced
by Belghiti with side-to-side cavocaval anastomosis [4].
Nevertheless, very few improvements have been introduced
in the surgical technique with regard to tissue preparation
and sealing the blood vessels during recipient hepatectomy.
Due to end-stage liver disease and the recipients’ general
and coagulatory condition, hepatectomy carries the risk of
severe blood loss (BL), which can impair the outcome after
LT. Usually, recipient hepatectomy is carried out as a com-
bination of sharp dissection of the hepatic adhesions to the
abdominal wall and the diaphragm and clip or suture
ligature of small retrohepatic caval vein branches [5].
With advances in surgical procedures and equipment,
modern technologies have been introduced that have
shortened operation time and improved surgical outcomes.
Exquisite equipment for liver parenchymal transection,
such as Cavitron ultrasonic surgical aspirator (Integra Life-
Sciences, Plainsboro NJ, USA), ultrasonic dissector (USD),
LigaSure™ (LS; Covidien, Medtronic, Minneapolis, MN,
USA), and TissueLink (Medtronic, Minneapolis, MN,
USA), can also be used to reduce hemorrhage in liver re-
section [6]. The ultrasonic scalpel (Ethicon, Bridgewater,
NJ, USA) is a USD that cuts and coagulates tissue using
ultrasound at frequencies higher than those used with an
ultrasonic aspirator [7]. This device can also serve as a
grasper and basically uses a blade that oscillates at 55 kHz,
thus producing heat and enabling coagulation of vessels.
Recently, its use and potential advantages in open liver
resection have been demonstrated. The main technical
advancement in this field relates to decreased intraop-
erative bleeding [8, 9]. Olmez et al. [10] described dissection
of the small retrohepatic veins with a USD (HARMONIC™
scalpel; Ethicon) during recipient hepatectomy. Their results
showed that this method is safe when compared with
conventional knot-tying ligation regarding intra- and
postoperative bleeding rate.
The LS electrothermal bipolar vessel-sealing device is
another alternative; it applies electrothermal bipolar
coagulation and dissection in one step. The LS dissection
device seals the tissue first, before it is divided; both tasks
are performed with the same device. This may prevent
severe bleeding. Furthermore, the sealing device is capable
of coping with small liver veins that can be sealed and
divided safely without the need for sutures or clips, the
latter of which are known for interfering with sufficient
“tangential” clamping of the inferior vena cava (IVC) for
side-to-side cavocavostomy during piggyback LT [11]. In
2012, Lamattina et al. [12] reported the use of LS devices
for recipient hepatectomy in LT. They concluded that LS
vessel sealing was an efficient method and that vessel
sealing of the caval and portal veins as well as other struc-
tures could be safely performed in the setting of end-stage
liver disease.
To our knowledge, no randomized clinical trial has
been conducted to compare various innovative dissec-
tion methods against the standard techniques used for
recipient hepatectomy. While LS and USD have been
proven to be used safely in several major surgical proce-
dures, including liver resection [13–20], their ability to
reduce BL in LT recipient hepatectomy has not yet been
evaluated systematically.
Methods/design
This is a single-center, prospective, randomized, controlled,
parallel, three-armed, confirmatory, open trial. This trial is
designed to evaluate the potential beneficial effects (super-
iority design) of using an LS device and USD for recipient
hepatectomy during LT. Furthermore, the practicability of
these methods is to be investigated. Both the duration of
the procedure and the BL during both the entire surgery
and the hepatectomy phase of transplant are of interest.
Hypotheses
Null hypotheses:
• The intraoperative BL does not differ in any clinically
relevant extent between the control group and USD with
(H01): BL 1 = BL 2.
• The intraoperative BL does not differ in any clinically
relevant extent between the control group and LS with
(H02): BL 1 = BL 3.
Alternative hypotheses:
• The intraoperative BL differs in a clinically relevant
extent between the control group and USD with (H11):
BL 1 ≠ BL 2.
• The intraoperative BL differs in a clinically relevant
extent between the control group and LS with (H12): BL
1 ≠ BL 3.
Setting
This investigator-initiated trial is set at a single referral
center which is specialized in visceral transplant surgery.
All LTs are carried out within a structured, interdiscip-
linary LT program that has been externally reviewed and
accredited.
Outcome measures
Primary endpoint
 Total BL during surgical procedure
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Secondary endpoints
 BL during recipient hepatectomy
 Time from skin incision to end of hemostasis after
hepatectomy
 Time from skin incision to end of skin closure
 Hemodynamic status during surgery: Data on the
mean arterial pressure and central venous pressure
(CVP) will be obtained at the beginning of
hepatectomy after incision and adhesiolysis.
 Coagulation state: International normalized ratio
(INR), partial thromboplastin time (PTT), and
platelet counts of patients will be recorded pre- and
postoperatively until postoperative day (POD) 10.
 Hemoglobin (Hb) level: Hb levels of patients will be
recorded pre- and postoperatively until POD 10.
 The number of units of packed red blood cells
(PRBC) transfused during surgery
 The number of fresh frozen plasma (FFP) units
transfused during surgery
 The number of platelet units transfused during
surgery
 Postoperative PRBC and FFP transfusion until POD 10
 Postoperative bleeding: Postoperative hemorrhaging
until POD 10 will be recorded and classified as
defined by Dindo et al. [21].
 Postoperative morbidity: Postoperative morbidity
will be recorded and classified as defined by Dindo
et al. [21].
 Retransplant rate
 Conversion rate to alternative methods during
recipient hepatectomy in LS and USD groups
Procedures and methods
General description
After incision through the abdominal wall, depending on
the randomization result, the electrothermal bipolar vessel
sealing device (“LS”, LigaSure™ Maryland Jaw 23 cm Open
Instrument; Covidien plc), an ultrasound dissector (“USD”,
HARMONIC ACE®+7 Shears; Ethicon), or standard
methods applying titanium clips and ligations will be
used for mobilization of the liver from its adhesions
and ligaments as well as for dissection and coagulation
of retrohepatic IVC branches and other small blood
vessel-bearing structures. Tissue coagulation and dissection
will be carried out in small portions according to the man-
ufacturer’s instructions. The dissection of the small blood
vessels and the connective tissue in the hepatoduodenal
ligament will also be carried out with LS or USD in the
experimental groups, whereas the common bile duct,
hepatic artery, and portal vein, as well as the major
hepatic veins (left, middle, and right), will be divided
with endovascular staplers or conventional knot-tying
ligations.
Therapeutic effects
Previous studies have reported that both LS and USD
devices can be used safely for recipient hepatectomy in LT
[10–12]. High-volume LT centers have reported intraoper-
ative BL with average values between 1000 and 2100 ml
[22–24]. In our experience, BL during LT could be
reduced to about 835 (± 560) ml using LS for recipient
hepatectomy [11].
Undesirable effects/risks Participation in the trial will
not cause additional invasive treatment (e.g., venous
puncture for blood sampling) for the subjects. Like any
other surgical procedure, freeing the liver from its adhe-
sions and ligaments and dissecting the retrohepatic IVC
branches bears the risk of bleeding and impairs other
anatomical structures in the operating field. Nevertheless,
preparation and dissection using LS and USD have been
proven to reliably control bleeding in daily use during a
variety of surgical procedures. A systematic review of
randomized controlled trials in which LS was compared
with other vessel-sealing devices did not reveal any safety
concerns associated with the method [25]. Because LS and
USD will be applied according to their designated indica-
tion within the approved parameters, no unreasonably
hazardous risks are expected.
Blinding
Blinding the surgical staff is impossible due to the use of
different methods in the three groups under investigation.
Because the primary endpoint “total BL” will be precisely
recorded during surgery by independent staff and second-
ary endpoints are objective physiological findings, blinding
of the subjects is not needed. Therefore, the open design
is not expected to cause any avoidable bias.
Randomization protocol
Sixty-nine LT recipients are expected to be randomized
into three groups of at least 23 patients each:
 LS group
 USD group
 Control group, using conventional bipolar
coagulation devices, surgical suture ligatures, and
surgical clips (or any dissecting/coagulating device
other than LS)
Randomization will be performed using the “block
randomization” method. Each block will contain multiple
balanced combinations of the three groups: LS, USD, and
control. Blocks will be randomly chosen (using simple
randomization software with Excel® [Microsoft, Redmond,
WA, USA]), and assignment of the participants to the
respective groups will be determined. Randomization will
be performed at any time between the inclusion of the
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patients according to the above-listed inclusion criteria
and the beginning of recipient hepatectomy. Randomization
will be performed by a member the clinical trial center
(Klinisches Studien Zentrum [KSC]) of the surgical
department of the University Hospital Heidelberg who
is not otherwise involved in the trial. Afterward, the
staff will personally inform the responsible surgeon
about the treatment group to which the patient has
been randomized.
Inclusion criteria
 Allocation of donor liver via Eurotransplant (Leiden,
The Netherlands) to recipient
 Recipients must be aged 18 years or older
 A signed written informed consent for participation
in the trial
Exclusion criteria
 High urgency state of recipient
 Previous LT
 Combined organ transplant
 Inability to give informed consent
Sample size estimation
The total BL during piggyback LT usually ranges from
1000 to 2100 ml [22–24, 26]. Based on our own preliminary
clinical experience on the use of the LS device for recipient
hepatectomy, a reduction in BL during LT from 1500 ml to
835 ml with an SD of 560 ml can be expected. Because
these results were obtained in an uncontrolled, retrospect-
ive study in which all procedures were performed by a
single, very experienced surgeon, we have added a “buffer”
of 200 ml in favor of a conservative yet robust sample size
calculation. Therefore, a reduction in BL from 1500 ml to
1035 ml was chosen for this trial. This effect could be
confirmed as statistically significant with a two-sided t test
at a power of 80% and an alpha of 0.025 as well as a
superiority margin of 50 ml with 23 patients in either
group. Hence, at least 69 patients in total will be included
in the intention-to-treat (ITT) analysis. Differences in the
per-protocol and ITT analyses will be of certain interest
with respect to the feasibility of the methods under
investigation.
Course of the study
All LT patients who meet our inclusion/exclusion criteria
will be informed about the study procedures and their
potential benefits. Possible side effects will be clearly
declared. Then the patients will be asked to give written
consent to participate in the trial via a trial investigator.
Baseline clinical and demographic data of the eligible
patients will be recorded. Laboratory data will be recorded
using routine laboratory tests, which will be performed
over the course of the perioperative clinical routine. The
patient will be randomized to one of the study arms
according to the randomization protocol, and the surgical
team will be informed at the time of operation. Figure 1
shows the trial flow diagram.
The entire BL from skin incision to skin closure is
defined as “intraoperative BL.” To assess the exact amount
of hemorrhage, the volume of fluid in the suction con-
tainer(s) that are used during the procedure will be
recorded in a case report form (CRF) at the end of skin
closure procedures. All ascites will be evacuated after
opening the abdomen, and the respective amount in
milliliters will be documented. Furthermore, the numbers
of all small and big surgical swabs will be recorded. All
swabs together will be weighed by the end of skin closure
procedures along with the drip-catching container in
which they are collected. The exact weight in grams will
be recorded in the CRF. The exact amount of rinse fluid
in milliliters that is used during the procedure will also be
recorded in the CRF.
The calculation of total BL will be as follows. The suc-
tion container fluid volume (in milliliters) will be added to
the weight (in grams) of all surgical swabs at the end of
skin closure procedures (A). The difference of the density
of the rinse solution (isotonic sodium chloride solution)
and blood is approximately 0.055 g/cm3. Regarding the ac-
curacy of these measurements, this difference is clinically
irrelevant.
The volume of the entire rinse fluid (in milliliters) that
is used during the procedure and the amount of ascites
(in milliliters) will be added to the known dry weight (in
grams) of the respective number of surgical swabs that
are used during the procedure and the known dry
weight of the drip-catching swab container (B). The
total BL is defined as “A” minus “B” in milliliters.
Protocol deviations will be recorded.
After the transplant, the routine care protocols (the
same as other LT patients) will be performed, and at
each visit, the patient will be assessed for BL, transfu-
sion, and postoperative complications. The laboratory
tests, including PTT and INR, will be performed in the
clinical routine prior to operation as well as 1, 3, 7, and
10 days after operation and at discharge. During the
study period, all postoperative surgical complications
will be recorded. All study-related data will be handled
and stored by the KSC data center. The enrollment period
is estimated to be 36 months, with the last patient being
enrolled at 39 months.
Monitoring
Surgical monitoring will be done by intraoperative
photographs (to be taken by a member of the KSC) of the
procedure being performed according to the randomization
result. This will include the situs after opening the
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abdominal wall, the use of the instrument in the experi-
mental arms, and the ventral surface of the caval vein
after removal of the recipient’s liver.
Patient time schedule and documentation
Visit day − 1 After the inclusion and exclusion criteria
are evaluated, if patients are eligible for participation
in the study, the following baseline data will be
documented:
Demographic characteristics:
 Gender (female/male)
 Age (years)
 Height (cm)
 Weight (kg)
Baseline clinical data:
 Reason for transplant
 Model for End-Stage Liver Disease score
 Baseline laboratory values
 American Society of Anesthesiologists score
(according to the anesthesiologist’s protocol)
Fig. 1 Flowchart of the SEALIVE trial according to Consolidated Standards of Reporting Trials (CONSORT) guidelines
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 Comorbidities (cardiac, pulmonary, renal,
autoimmune, hematologic, and infectious; previous
abdominal surgery)
 Medication
Visit day of surgery The following data will be recorded
intraoperatively according to the study endpoints:
 Duration of hepatectomy
 Duration of whole procedure
 BL during the hepatectomy
 BL during whole procedure
 Transfusion requirements of PRBC and FFP
 Hemodynamic status during hepatectomy and whole
procedure (including CVP)
 Presence of portal venous cavernous transformation
and/or umbilical varices
 Feasibility of trial methods (rate of conversion to
alternative methods during recipient hepatectomy in
the LS, USD, and control groups, as well as protocol
violations)
 Documentation of the surgeon’s experience in LT
(number of cases) and the user’s experience with the
applied method (frequent/rare)
Visit PODs 1, 3, 5, 7, and 10 and day of discharge
The following data will be recorded postoperatively or
taken during the patient’s hospital stay:
 Transfusion requirements
 Hb and platelet count, coagulation parameters
 Surgical complications (i.e., bleeding at site of LS
and USD use)
 Serious adverse events (SAE)/treatment-emergent
adverse events (TEAE)
Visit PODs 30 and 90 SAE/TEAE, complications, and
mortality will be recorded until POD 90. Figure 2 gives
an overview of study visits and documentation of data
for each patient.
Accompanying therapy The participant will receive
routine care and treatment according to the University
Hospital Heidelberg’s manual for LT [27].
Safety laboratory Not applicable.
Safety objectives and assessment of safety To assess
the safety of the surgical procedures under investigation,
all incidences of TEAEs and SAEs will be documented
and evaluated. We will collect only intervention-related
events that occur during surgery and follow-up. All
TEAEs/SAEs and intervention-related adverse effects
will be documented on separate forms and analyzed as
part of the safety analysis.
SAEs SAEs are defined as any untoward medical occur-
rence that meets one or more of the following criteria:
Fig. 2 Visit schedule and documentation according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines
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 Results in death
 Is life-threatening
 Requires inpatient hospitalization or prolongation of
existing hospitalization
 Results in persistent or significant disability/
incapacity
 Requires other intervention(s) to prevent persistent
impairment or damage
Documentation of SAEs From the time that the patient
approves and signs the informed consent to either the
study’s end or the patient’s withdrawal, SAEs must be
documented on an SAE form available in the investigator
study file. All SAEs that occur from the time between the
day of inclusion and discharge must be documented on an
SAE form in the CRF. The SAE form will contain the
following information: the name of attending physician,
a detailed description of the SAE (including event,
beginning and duration, severity, outcome, causality to
trial intervention, therapy/interventions taken), the
consequence for the trial, and a dated signature of the
attending physician.
Classification of SAEs
 Classification of outcome: The outcome of an SAE
at the time of last contact with the patient is
classified as follows:
– Ongoing: Signs and symptoms of the SAE
continue.
– Recovered completely: All signs and symptoms of
the SAE have disappeared.
– Recovered with sequelae: Acute signs and
symptoms of the SAE have disappeared, but the
sequelae caused by the SAE still exist.
– Death: The SAE has caused the patient’s death. If
a subject has experienced more than one SAE,
only the outcome for the SAE directly
responsible for death is classified as “death,”
whereas the other SAEs are classified according
to their specific outcome.
– Unknown: The outcome is unknown or is
implausible, and there is no possibility to
complete or verify the information.
 Classification of intensity
– Mild: a temporary event that is well tolerated by
the subject
– Moderate: an event that results in discomfort for
the subject and impairs his/her normal activity
– Severe: an event that results in substantial
impairment of normal activities of subject
 Classification of causality
– Unrelated: an SAE that does not follow a
reasonable temporal sequence from trial
treatment and that is likely to have been
produced by the subject’s clinical state, other
modes of therapy, or other known etiology
– Possibly related: An SAE that has a reasonable
possibility of having been caused by trial
treatment. The SAE has a timely relationship to
trial treatment(s); however, the event follows no
known pattern of response, and an alternative
cause seems more likely or there is significant
uncertainty about the cause of the event.
– Definitely related: There is a reasonable
possibility that the event may have been caused
by trial treatment. A certain event has a strong
temporal relationship, and an alternative cause is
unlikely.
– Not assessable: There is insufficient or
incomplete evidence to make a clinical judgment
regarding the causal relationship to trial
treatment.
 Classification of countermeasures: The
countermeasures will be documented according to
the following rules:
 None: no action taken
 Drug treatment: newly prescribed medication or
change in dose of a medication
 Others: other countermeasures (e.g., an operative
procedure)
Methods of data collection
SAEs will be documented until the end of follow-up of
each patient. The results will be evaluated in the clinical
results report. Each patient will be asked to report the
occurrence of any event to the investigator. At each visit,
the investigator will ask the patient if he or she has
experienced any of the SAEs noted since the last visit.
Each SAE must be reported in the SAE form available in
the investigator study file.
Reporting of SAEs
SAEs must be reported by the attending physician to the
principal investigator within 24 hours after the SAE
becomes known. The initial report must be as complete as
possible, including details of the current illness, the SAE,
and an assessment of the causal relationship between the
event and trial treatment.
Emergency treatment
During and following the subject’s participation in the
trial, the investigator must ensure that adequate medical
care is provided. The subject must receive adequate
treatment in any clinical situation, including any emergen-
cies and outcomes of the patient that must be checked.
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Termination criteria
Study termination To assess the trial’s safety, deaths
and SAEs will be documented on separate forms and
analyzed within the safety analysis. The principal inves-
tigator, in consultation with key research associates and
the biostatistician, may terminate the trial at any time.
Reasons for termination may include high mortality rate
as well as incidence or severity of SAEs that indicate a po-
tential health hazard caused by either the study treatment
or external evidence which requires premature termin-
ation of the trial. Due to the open nature of the trial and
the use of fully approved techniques, a data monitoring
committee is not necessary in this single-center trial.
Patients’ withdrawal
A patient is taken out of the study if he/she withdraws
his/her consent to participate at any time without the
need to state the reason and without disadvantages for
further medical care. The withdrawal of a patient will be
documented in the CRF.
Statistical design
Dichotomous data and counts will be presented as frequen-
cies. Continuous data will be presented as mean with SD or
as median value with a range. Statistical interpretation of the
data includes multiple t tests with Bonferroni correction for
parametric data (including BL) and the Kruskal-Wallis test
for nonparametric data. The chi-square test will be used for
categorical data. The significance level will be set at alpha ≤
0.05 (after a Bonferroni adjustment when applicable) repre-
senting 95% confidence.
Ethical and legal aspects
Ethical basics The study protocol is in accord with the
2013 version of the Helsinki declaration. Participants
will voluntarily enroll in the study; consent may be with-
drawn at any time, without giving reasons and without
disadvantages for further medical care. Execution of the
trial is to be carried out by the KSC, an internal division of
the Department of General, Visceral, and Transplantation
Surgery of the University Hospital Heidelberg. Study
personnel will not be additionally compensated for execu-
tion of the trial. There is no restricted external financial
support for the trial. Participants in the trial will not be
compensated financially or otherwise. Because the entire
trial will incorporate fully licensed and approved methods
in the regular treatment course, no additional compensa-
tion for harmful outcomes will be provided.
Patient information/informed consent
Patients will be informed in writing and verbally about
the nature and scope of the planned study before the
start of the study, in particular about the possible benefits
to their health and potential risks. Patient approval will be
documented by the patient’s signature on the informed
consent form. Upon resignation from the study, either
data will be destroyed or the patient will be asked whether
he/she agrees with further evaluation of the material
collected during the trial.
Legal basics
Vote of the ethics committee The study protocol will
be submitted for review before the trial’s start date by
the ethics committee of the University of Heidelberg’s
medical faculty. The study will not begin until a written
vote from the ethics committee has been received. All
relevant changes to the trial protocol will be announced
to the ethics committee.
Data protection/insight into original patient records
The names of the patients and all other confidential infor-
mation will be subject to medical confidentiality and
the provisions of the German Federal Data Privacy Law
(Bundesdatenschutzgesetz [BDSG]) and the European
Union General Data Protection Regulation. Transfer of
patient data is only possible in pseudonymized form.
Third parties will not have access to the original patient
records.
Discussion
This trial will address the important step of recipient
hepatectomy during LT because there is little quality
data on the implications of this surgical procedure. Of
note is the fact that hepatectomy is carried out in patients
with end-stage liver disease with normal impaired liver
function that leads to coagulopathy, portal hypertension,
and thrombocytopenia due to hypersplenism. In this
context, finding a portal venous variceal conversion often
enhances the already elevated risk of severe intraoperative
hemorrhage. Intraoperative BL is associated with inferior
outcome after LT, even though the true cause is often-
times hard to pinpoint [28, 29]. Other than donor organ
quality and the condition of the recipient, intraoperative
BL is potentially modifiable and therefore deserves special
attention to improve the patient’s outcome after LT.
The SEALIVE trial is designed to detect and evaluate
quantitative reduction in BL. Reducing BL has been
proven to be relevant because it has been shown that
the average amount of BL in liver resection could be
reduced by approximately 400 ml if no transfusion of
blood products was necessary [30]. Although intraoper-
ative transfusion requirements of blood products have
been shown to correlate with the outcome, they are
subject to individual decision-making processes of the
anesthesiologists and the center-specific routine [31, 32].
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The potential limitation of this unblinded trial design is
not believed to incorporate unnecessary bias, because the
surgeon cannot be blinded in any case, and the primary
endpoint (BL) will be precisely measured intraoperatively
by independent staff (Additional file 1).
Trial status
The latest protocol version of the SEALIVE trial is version
1.6 (June 16, 2018). Recruitment of patients was planned
to begin in July 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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